Form 4: Supernus Pharmaceuticals SVP, Chief Medical Officer Jonathan Rubin Reports Stock Option Grant and Restricted Stock Unit Award

Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 19, 2025, Rubin was granted an option to purchase 20,000 shares of Supernus common stock at an exercise price of $33.52.
• The options vest in four equal annual installments beginning on February 19, 2026, and expire on February 19, 2035.
• Rubin also received 4,500 restricted stock units (RSUs) which will vest in four equal annual installments beginning on February 19, 2026.
• Each RSU represents the right to receive one share of Supernus common stock upon vesting.
• Rubin also acquired 310 shares of common stock through the Issuer's Employee Stock Purchase Plan.
• Following these transactions, Rubin directly owns 6,905 shares of Supernus common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive compensation, which is neither particularly positive nor negative.

Positives

• The grant of stock options and RSUs to a key executive like the Chief Medical Officer can be seen as an incentive to drive company performance.

Future Outlook

The vesting schedules for the stock options and RSUs suggest a multi-year commitment from the executive.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include a mix of salary, bonus, stock options, and restricted stock units.
• The specific terms of these grants, such as vesting schedules and exercise prices, are typically benchmarked against peer companies to ensure competitiveness.
• Companies like Teva, Mylan (now Viatris), and Amgen also utilize similar compensation strategies to incentivize their executives.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term value creation.
• Employees may see the grants as a reflection of the company's commitment to its leadership team.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Supernus Pharmaceuticals, SUPN, Jonathan Rubin, Executive Compensation